Table 4.
Recent studies reporting hematopoietic stem cell transplant outcomes for patients with Fanconi anemia and pre-HSCT evolution to myeloid malignancies
| Reference | Patients (n) | Era of HSCT | Conditioning | Survival |
|---|---|---|---|---|
| Mitchell et al. (2014)35 | MM: 21 | 1988-2011 | Various | All MM: 5-year OS 33% |
| Bierings et al. (2018)13 | Total: 199 MM: 54 |
1991-2014 | Various | MDS: 4-year OS 48% AML: 4-year OS 17% |
| Giardino et al. (2020)32 | MM: 74 | 1999-2016 | Various | All MM: 5-year OS 42% 5-year EFS 39% |
| Bernard et al. (2021)33 | Total: 82 MM: 11 |
1999-2018 | Most fludarabine + cyclophosphamide | All MM: 5-year OS 40% |
| Mehta et al. (2017)15 | Total: 45 MM: 11 |
2009-2014 | Low-dose busulfan + cyclophosphamide, fludarabine, ATG | MDS: 3-year OS 63.6% |
| Chattopadhyay et al. (2023)34 | Total: 60 MM: 10 |
1990-2021 | Low-dose busulfan + fludarabine | All MM: 5-year OS 46% |
ATG, antithymocyte globulin; EFS, event-free survival.